John R Kirwan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5562431/publications.pdf

Version: 2024-02-01

83	5,272	35	72
papers	citations	h-index	g-index
89	89	89	5243
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Effect of Glucocorticoids on Joint Destruction in Rheumatoid Arthritis. New England Journal of Medicine, 1995, 333, 142-147.	13.9	774
2	Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0. Journal of Clinical Epidemiology, 2014, 67, 745-753.	2.4	625
3	Patients and professionals as research partners: Challenges, practicalities, and benefits. Arthritis and Rheumatism, 2006, 55, 676-680.	6.7	214
4	Effects of glucocorticoids on radiological progression in rheumatoid arthritis. The Cochrane Library, 2007, , CD006356.	1.5	201
5	Articular indices of joint inflammation in rheumatoid arthritis. Correlation with the acute-phase response. Arthritis and Rheumatism, 1987, 30, 618-623.	6.7	168
6	Fatigue in rheumatoid arthritis: time for a conceptual model. Rheumatology, 2011, 50, 1004-1006.	0.9	163
7	Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Annals of the Rheumatic Diseases, 2013, 72, 204-210.	0.5	160
8	Incorporating the patient perspective into outcome assessment in rheumatoid arthritis-progress at OMERACT 7. Journal of Rheumatology, 2005, 32, 2250-6.	1.0	152
9	Emerging Guidelines for Patient Engagement in Research. Value in Health, 2017, 20, 481-486.	0.1	144
10	Measuring fatigue in rheumatoid arthritis: A crossâ€sectional study to evaluate the Bristol Rheumatoid Arthritis Fatigue Multiâ€Dimensional questionnaire, visual analog scales, and numerical rating scales. Arthritis Care and Research, 2010, 62, 1559-1568.	1.5	140
11	Non-pharmacological interventions for fatigue in rheumatoid arthritis. The Cochrane Library, 2013, , CD008322.	1.5	134
12	Patient education for adults with rheumatoid arthritis. The Cochrane Library, 2003, , .	1.5	131
13	Outcomes from the Patient Perspective Workshop at OMERACT 6. Journal of Rheumatology, 2003, 30, 868-72.	1.0	129
14	Systematic review of rheumatoid arthritis patient education. Arthritis and Rheumatism, 2004, 51, 1045-1059.	6.7	120
15	Reduced Loss of Hand Bone Density With Prednisolone in Early Rheumatoid Arthritis. Archives of Internal Medicine, 2005, 165, 1293.	4.3	103
16	Outcomes generated by patients with rheumatoid arthritis: how important are they?. Musculoskeletal Care, 2005, 3, 131-142.	0.6	98
17	Collaboration with patients in the design of patientâ€reported outcome measures: Capturing the experience of fatigue in rheumatoid arthritis. Arthritis Care and Research, 2010, 62, 1552-1558.	1.5	90
18	The patient perspective on remission in rheumatoid arthritis: †You've got limits, but you're back to being you again'. Annals of the Rheumatic Diseases, 2015, 74, 1004-1010.	0.5	71

#	Article	IF	CITATIONS
19	Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients. Rheumatology, 2017, 56, 1573-1578.	0.9	71
20	Biologic interventions for fatigue in rheumatoid arthritis. The Cochrane Library, 2016, 2016, CD008334.	1.5	60
21	Glucocorticoids: action and new therapeutic insights in rheumatoid arthritis. Current Opinion in Rheumatology, 2007, 19, 233-237.	2.0	54
22	Updating the OMERACT Filter: Implications for Patient-reported Outcomes. Journal of Rheumatology, 2014, 41, 1011-1015.	1.0	54
23	Reducing arthritis fatigue impact: two-year randomised controlled trial of cognitive behavioural approaches by rheumatology teams (RAFT). Annals of the Rheumatic Diseases, 2019, 78, 465-472.	0.5	48
24	Patient education programmes for adults with rheumatoid arthritis. BMJ: British Medical Journal, 2002, 325, 558-559.	2.4	47
25	Recommendations for the Involvement of Patient Research Partners (PRP) in OMERACT Working Groups. A Report from the OMERACT 2014 Working Group on PRP. Journal of Rheumatology, 2016, 43, 187-193.	1.0	46
26	Rheumatoid Arthritis: Disease-modifying Antirheumatic Drugs. Clinics in Rheumatic Diseases, 1983, 9, 581-599.	1.2	43
27	Successful Stepwise Development of Patient Research Partnership: 14 Years' Experience of Actions and Consequences in Outcome Measures in Rheumatology (OMERACT). Patient, 2017, 10, 141-152.	1.1	41
28	The effect of therapeutic glucocorticoids on the adrenal response in a randomized controlled trial in patients with rheumatoid arthritis. Arthritis and Rheumatism, 2006, 54, 1415-1421.	6.7	40
29	The Impact Triad (Severity, Importance, Self-management) as a Method of Enhancing Measurement of Personal Life Impact of Rheumatic Diseases. Journal of Rheumatology, 2011, 38, 191-194.	1.0	39
30	Reliability and sensitivity to change of the Bristol Rheumatoid Arthritis Fatigue scales. Rheumatology, 2013, 52, 1832-1839.	0.9	39
31	Patient Perspective on Outcomes in Rheumatology — A Position Paper for OMERACT 9. Journal of Rheumatology, 2009, 36, 2067-2070.	1.0	38
32	Effect of novel therapeutic glucocorticoids on circadian rhythms of hormones and cytokines in rheumatoid arthritis. Annals of the New York Academy of Sciences, 2010, 1193, 127-133.	1.8	38
33	Progress on Incorporating the Patient Perspective in Outcome Assessment in Rheumatology and the Emergence of Life Impact Measures at OMERACT 9. Journal of Rheumatology, 2009, 36, 2071-2076.	1.0	36
34	Stiffness is more than just duration and severity: a qualitative exploration in people with rheumatoid arthritis. Rheumatology, 2015, 54, 615-622.	0.9	35
35	Progress since OMERACT 6 on including patient perspective in rheumatoid arthritis outcome assessment. Journal of Rheumatology, 2005, 32, 2246-9.	1.0	28
36	The risks of local and systemic corticosteroid administration. Bailliere's Clinical Rheumatology, 1990, 4, 305-332.	1.0	27

#	Article	IF	Citations
37	Clinical and psychological outcomes of patient education in rheumatoid arthritis. Musculoskeletal Care, 2005, 3, 1-16.	0.6	27
38	Lowâ€dose glucocorticoid therapy in rheumatoid arthritis: an obligatory therapy. Annals of the New York Academy of Sciences, 2010, 1193, 123-126.	1.8	26
39	Alleviation of morning joint stiffness by low-dose prednisone in rheumatoid arthritis is associated with circadian changes in IL-6 and cortisol. International Journal of Clinical Rheumatology, 2011, 6, 241-249.	0.3	26
40	Sensitivity to change of the Rheumatoid Arthritis Selfâ€Efficacy scale (RASE) and predictors of change in selfâ€efficacy. Musculoskeletal Care, 2008, 6, 49-67.	0.6	23
41	Patient Perspective: Choosing or Developing Instruments. Journal of Rheumatology, 2011, 38, 1716-1719.	1.0	23
42	Men, rheumatoid arthritis, psychosocial impact and self-management: A narrative review. Journal of Health Psychology, 2016, 21, 2168-2182.	1.3	23
43	"You Obviously Just Have to Put on a Brave Faceâ€. A Qualitative Study of the Experiences and Coping Styles of Men With Rheumatoid Arthritis. Arthritis Care and Research, 2017, 69, 330-337.	1.5	23
44	"An Impediment to Living Life― Why and How Should We Measure Stiffness in Polymyalgia Rheumatica?. PLoS ONE, 2015, 10, e0126758.	1.1	23
45	Measuring sensation in the feet of patients with rheumatoid arthritis. Musculoskeletal Care, 2006, 4, 12-23.	0.6	21
46	†Everyone assumes a man to be quite strong': Men, masculinity and rheumatoid arthritis: A caseâ€study approach. Sociology of Health and Illness, 2018, 40, 115-129.	1.1	21
47	Updating the OMERACT Filter: Core Areas as a Basis for Defining Core Outcome Sets. Journal of Rheumatology, 2014, 41, 994-999.	1.0	20
48	Remission in Rheumatoid Arthritis: Working Toward Incorporation of the Patient Perspective at OMERACT 12. Journal of Rheumatology, 2016, 43, 203-207.	1.0	20
49	SYSTEMIC LOW-DOSE GLUCOCORTICOID TREATMENT IN RHEUMATOID ARTHRITIS. Rheumatic Disease Clinics of North America, 2001, 27, 389-403.	0.8	19
50	Updating the OMERACT Filter at OMERACT 11. Journal of Rheumatology, 2014, 41, 975-977.	1.0	19
51	Group cognitive–behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations. Health Technology Assessment, 2019, 23, 1-130.	1.3	18
52	Patient education in rheumatoid arthritis. Current Opinion in Rheumatology, 1990, 2, 336-339.	2.0	16
53	Outcome Measures in Polymyalgia Rheumatica. A Systematic Review. Journal of Rheumatology, 2015, 42, 2503-2511.	1.0	14
54	Coping Strategies, Psychological Impact, and Support Preferences of Men With Rheumatoid Arthritis: A Multicenter Survey. Arthritis Care and Research, 2018, 70, 851-860.	1.5	14

#	Article	IF	Citations
55	Translating patient reported outcome measures: methodological issues explored using cognitive interviewing with three rheumatoid arthritis measures in six European languages. Rheumatology, 2016, 55, 1009-1016.	0.9	13
56	Developing a group intervention to manage fatigue in rheumatoid arthritis through modifying physical activity. BMC Musculoskeletal Disorders, 2019, 20, 194.	0.8	12
57	Corticosteroid therapy in rheumatoid arthritis. Bailliere's Clinical Rheumatology, 1990, 4, 621-647.	1.0	11
58	Stiffness Is the Cardinal Symptom of Inflammatory Musculoskeletal Diseases, Yet Still Variably Measured: Report from the OMERACT 2016 Stiffness Special Interest Group. Journal of Rheumatology, 2017, 44, 1904-1910.	1.0	11
59	Symptom control with low-dose glucocorticoid therapy for rheumatoid arthritis. Rheumatology, 2012, 51, iv14-iv20.	0.9	10
60	Reporting of Significance Levels Versus Pearson's Correlation Coefficient. Rheumatology, 1984, 23, 232-233.	0.9	9
61	Combination Therapy Including Glucocorticoids: The New Gold Standard for Early Treatment in Rheumatoid Arthritis?. Annals of Internal Medicine, 2012, 156, 390.	2.0	9
62	Physical activity interventions for fatigue in rheumatoid arthritis: a systematic review. Physical Therapy Reviews, 2017, 22, 12-22.	0.3	9
63	Efficacy, safety and mechanism of action of modified-release prednisone in rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease, 2012, 4, 159-166.	1.2	8
64	Identifying different typologies of experiences and coping strategies in men with rheumatoid arthritis: a Q-methodology study. BMJ Open, 2016, 6, e012051.	0.8	8
65	Biological treatment in rheumatoid arthritis: when to stop?. Lancet, The, 2014, 383, 288-289.	6.3	7
66	Low Dose Corticosteroids in Early Rheumatoid Arthritis. Drugs and Aging, 1996, 8, 157-161.	1.3	5
67	The analysis of a bivariate multi-state Markov transition model for rheumatoid arthritis with an incomplete disease history., 1999, 18, 1677-1690.		5
68	New modes of practice. Current Opinion in Rheumatology, 2004, 16, 125-129.	2.0	5
69	The Spirit of OMERACT: Q Methodology Analysis of Conference Characteristics Valued by Delegates. Journal of Rheumatology, 2015, 42, 1982-1992.	1.0	5
70	Development and validation of novel biomarker assays for osteoarthritis. PLoS ONE, 2017, 12, e0181334.	1.1	5
71	The benefit of low-dose glucocorticoid treatment in early rheumatoid arthritis may outweigh the risk: Comment on the editorial by Harris. Arthritis and Rheumatism, 2006, 54, 2031-2032.	6.7	4
72	Rheumatoid arthritis: previously untreated early disease. Clinical Evidence, 2016, 2016, .	0.2	4

#	Article	IF	CITATIONS
73	The intelligent use of systemic glucocorticoids in rheumatoid arthritis. Expert Review of Clinical Immunology, 2014, 10, 143-157.	1.3	3
74	Achieving consensus on minimum data items (including core outcome domains) for a longitudinal observational cohort study in rheumatoid arthritis. Rheumatology, 2017, 56, kew416.	0.9	3
75	THE POTENTIAL OF COMPUTER APPLICATIONS IN RHEUMATOLOGY. Rheumatology, 1987, 26, 3-4.	0.9	2
76	The Use of Guidelines for Managing and Treating Osteoarthritis. Disease Management and Health Outcomes, 1998, 3, 131-142.	0.3	1
77	Early rheumatoid arthritis: combination therapy with disease-modifying antirheumatic drugs and low-dose glucocorticoids?. Nature Clinical Practice Rheumatology, 2006, 2, 182-183.	3.2	1
78	Does treatment with glucocorticoids or with disease-modifying antirheumatic drugs reduce the rate of radiographic progression in rheumatoid arthritis? Comment on the article by Abu-Shakra et al. Arthritis and Rheumatism, 1999, 42, 1066-1066.	6.7	0
79	The use of glucocorticoids in preventing joint destruction: Comment on the review by Schett et al. Arthritis and Rheumatism, 2009, 60, 1202-1203.	6.7	0
80	Revitalising glucocorticoids for (rheumatoid) arthritis. Clinical Medicine, 2010, 10, 159-160.	0.8	0
81	Item Development and Face Validity of the Rheumatoid Arthritis Patient Priorities in Pharmacological Interventions Outcome Measures. Patient, 2016, 9, 103-115.	1.1	O
82	Systemic glucocorticoids in chronic arthritis. , 2001, , 175-190.		0
83	Systemic glucocorticoids in rheumatoid arthritis. , 2005, , 247-264.		O